ClinicalTrials.gg
CompletedNCT01915667Updated Sep 17, 2013

Oral Bioavailability of Two Solid Formulations of GLPG0634

A Phase 1 interventional study of 200 mg GLPG0634 as capsules, fasted and 200 mg GLPG0634 as tablets, fasted in Healthy, sponsored by Galapagos NV. Completed at 1 site in Belgium. Open to male participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-09-17.

Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
Male
01

Study summary

The purpose of the study is to evaluate the amount of compound present in the blood (relative bioavailability) after a single administration of GLPG0634 as a tablet versus a capsule in fasted conditions in male healthy subjects.

Also, the effect of food on the bioavailability of the tablet formulation will be studied as well as the safety and tolerability of single oral doses of GLPG0634 given either as capsule or tablet.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male, age 40-60 years
  • between 18-30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any condition that might interfere with the procedures or tests in this study
  • Drug or alcohol abuse
  • Smoking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    GLPG0634 capsule fasted

    Single dose of GLPG0634 as capsules in fasted condition

    Drug: 200 mg GLPG0634 as capsules, fasted

  • Experimental
    GLPG0634 tablet fasted

    Single dose of GLPG0634 as tablets in fasted condition

    Drug: 200 mg GLPG0634 as tablets, fasted

  • Active comparator
    GLPG0634 tablet fed

    Single dose of GLPG0634 as tablets in fed condition

    Drug: 200 mg GLPG0634 as tablets, fed

Interventions

  • Drug200 mg GLPG0634 as capsules, fasted

    single oral dose of 200 mg GLPG0634 given as capsules in fasted condition

  • Drug200 mg GLPG0634 as tablets, fasted

    single oral dose of 200 mg GLPG0634 given as tablets in fasted condition

  • Drug200 mg GLPG0634 as tablets, fed

    single oral dose of 200 mg GLPG0634 given as tablets in fed condition

06

What researchers measure

Primary outcomes

  1. The amount of GLPG0634 and metabolite in plasma after a single dose of GLPG0634 as capsules or tablets

    To characterize and compare the amount of GLPG0634 and metabolite in plasma (relative bioavailability) in male healthy subjects after a single administration of either a capsule or tablet formulation in a fasted condition. For the tablet formulation, also the amount of GLPG0634 and metabolite in plasma will be evaluated after fasting and in fed condition.

    Time frame: From predose (before first study drug administration) up to 144 hours post last study drug administration

Secondary outcomes

  1. The number of subjects with adverse events, abnormal lab tests, physical examinations, vital signs and ECG after a single dose of GLPG0634 as capsules or tablets

    To evaluate the safety and tolerability of GLPG0634 after a single oral dose as capsules or tablets, either fasted or fed, in male healthy subjects in terms of adverse events (AEs), abnormalities in laboratory tests, physical examinations, vital signs and electrocardiogram (ECG)

    Time frame: Between screening and 7-10 days after the last dose

07

Study locations

1 site
  • SGS LSS Clinical Pharmacology Unit Antwerp
    Antwerp, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2013
First posted
Aug 5, 2013
Start
Jul 2013
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Last update
Sep 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01915667
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Aug 5, 2013
Start date
Jul 2013
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Sep 17, 2013

Study contacts

Pille Harrison, MD
study director · Galapagos NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion